Fractal analysis of two-dimensional vascularity in primary prostate cancer and surrounding non-tumoral parenchyma

Pathology Research and Practice

Volumn 205, Issue 7, 2009, Pages 438-444

  Taverna, Gianluigi ^a   Colombo, Piergiuseppe ^a   Grizzi, Fabio ^a   Franceschini, Barbara ^a   Ceva Grimaldi, Giorgia ^a   Seveso, Mauro ^a   Giusti, Guido ^a   Piccinelli, Alessandro ^a   Graziotti, Pierpaolo ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Angiogenesis; Cancer; Fractal geometry; Prognosis; Prostate

Indexed keywords

CD34 ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGITAL IMAGING; FRACTAL ANALYSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TUMOR VASCULARIZATION;

AGED; ANTIGENS, CD34; CARCINOMA; FRACTALS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67349274673     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.12.019     Document Type: Article

References (38)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Nam R.K., Zhang W.W., Jewett M.A., et al. The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin. Cancer Res. 11 (2005) 8391-8397
3. Brawer M.K. Prostate-specific antigen: current status. CA Cancer J. Clin. 49 (1999) 264-281
4. Buhmeida A., Pyrhonen S., Laato M., and Collan Y. Prognostic factors in prostate cancer. Diagn. Pathol. 1 (2006) 4
5. Lamb D.S., Slaney D., Smart R., et al. Prostate cancer: the new evidence base for diagnosis and treatment. Pathology 39 (2007) 537-544
6. Collette L., Burzykowski T., and Schroder F.H. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur. J. Cancer 42 (2006) 1344-1350
7. Sooriakumaran P., Lovell D.P., Henderson A., et al. Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer. Clin. Oncol. (R. Coll. Radiol.) 17 (2005) 655-658
8. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
9. Concato J., Jain D., Li W.W., et al. Molecular markers and mortality in prostate cancer. BJU Int. 100 (2007) 1259-1263
10. Hlatky L., Hahnfeldt P., and Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Nat. Cancer Inst. 94 (2004) 883-893
11. Offersen B.V., Borre M., and Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur. J. Cancer 39 (2003) 881-890
12. Hida K., Hida Y., and Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci. 99 (2008) 459-466
13. Aird W.C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ. Res. 100 (2007) 158-173
14. Aird W.C. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds,. Circ. Res. 100 (2007) 174-190
15. Fidler I.J., and Ellis L.M. Neoplastic angiogenesis - not all blood vessels are created equal. N. Engl. J. Med. 351 (2004) 215-216
16. Grizzi F., Colombo P., Barbieri B., et al. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin. Cancer Res. 7 (2001) 3305-3307 Correspondence re: E. Sabo et al.
17. Grizzi F., Russo C., Colombo P., et al. Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer 5 (2005) 14
18. Di Ieva A., Grizzi F., Ceva-Grimaldi G., et al. Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. J. Anat. 211 (2007) 673-680
19. Di Ieva A., Grizzi F., Gaetani P., et al. Euclidean and fractal geometry of microvascular networks in normal and neoplastic pituitary tissue. Neurosurg. Rev. 31 (2008) 271-281
20. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal. Quant. Cytol. Histol. 30 (2008) 190-198
21. Bassingthwaighte J.B., Liebovitch L.S., and West B.J. Fractal Physiology (1994), Oxford University Press, New York
22. Hastings H.M., and Sugihara G. Fractals. A User's Guide for the Natural Sciences (1993), Oxford Science Publications, Oxford
23. Paumgartner D., Losa G., and Weibel E.R. Resolution effect on the stereological estimation of surface and volume and its interpretation in terms of fractal dimensions. J. Microsc. 121 (1981) 51-63
24. Losa G.A., and Nonnenmacher T.F. Self-similarity and fractal irregularity in pathologic tissues. Mod. Pathol. 9 (1996) 174-182
25. Mandelbrot B.B. The Fractal Geometry of the Nature (1983), Freeman, San Francisco
26. Kosari F., Munz J.M., Savci-Heijink C.D., et al. Identification of prognostic biomarkers for prostate cancer. Clin. Cancer Res. 14 (2008) 1734-1743
27. Steuber T., O'Brien M.F., and Lilja H. Serum markers for prostate cancer: a rational approach to the literature. Eur. Urol. 54 (2008) 31-40
28. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why?. Nat. Clin. Pract. Oncol. 4 (2007) 692-698
29. Cheng L., Davidson D.D., Lin H., et al. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 110 (2007) 1967-1972
30. Berney D.M., Fisher G., Kattan M.W., et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int. 100 (2007) 1240-1244
31. Berney D.M., Fisher G., Kattan M.W., et al. Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome. Histopathology 51 (2007) 452-457
32. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 (2003) 685-693
33. Ribatti D., Vacca A., and Dammacco F. New non-angiogenesis dependent pathways for tumour growth. Eur. J. Cancer 39 (2003) 1835-1841
34. Sakariassen P.Ø., Prestegarden L., Wang J., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc. Natl. Acad. Sci. USA 103 (2006) 16466-16471
35. Pezzella F., Pastorino U., Tagliabue E., et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151 (1997) 1417-1423
36. Passalidou E., Trivella M., Singh N., et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br. J. Cancer 86 (2002) 244-249
37. Wesseling P., van der Laak J.A., de Leeuw H., et al. Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. J. Neurosurg. 81 (1994) 902-909
38. Sardari Nia P., Hendriks J., Friedel G., et al. Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma. Histopathology 51 (2007) 354-361